Line 1: |
Line 1: |
− | Text
| + | '''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics.<ref>{{Cite journal|last=Geiersbach|first=Katherine B.|last2=Chen|first2=Hui|last3=Emmadi|first3=Rajyasree|last4=Haskell|first4=Gloria T.|last5=Lu|first5=Xinyan|last6=Liu|first6=Yajuan J.|last7=Swisshelm|first7=Karen|date=2020-06|title=Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group|url=https://pubmed.ncbi.nlm.nih.gov/32087595|journal=Cancer Genetics|volume=244|pages=11–20|doi=10.1016/j.cancergen.2020.02.002|issn=2210-7762|pmid=32087595}}</ref> |
| + | {| class="wikitable" |
| + | |'''Alteration''' |
| + | |'''Relevant Gene(s)''' |
| + | |'''CGC Evidence Level'''† |
| + | |'''Subgroup Association(s)''' |
| + | |- |
| + | |1q gain |
| + | |unknown |
| + | |2 |
| + | |Most common copy number alteration, often with 16q loss; all subtypes |
| + | |- |
| + | |8p11.2 amplification |
| + | |''[[FGFR1]]'', ''[[ZNF703]]'' |
| + | |2 |
| + | |METABRIC IntClust6, ER positive |
| + | |- |
| + | |8q24 amplification |
| + | |''[[MYC]]'' |
| + | |2 |
| + | |METABRIC IntClust9, ER positive |
| + | |- |
| + | |9p24 amplification |
| + | |''[[JAK2]], [[CD274]], [[PDCD1LG2]]'' |
| + | |2 |
| + | |Enriched in TNBC |
| + | |- |
| + | |10q23.3 loss or LOH |
| + | |''[[PTEN]]'' |
| + | |2 |
| + | |Enriched in TNBC and in lobular carcinoma |
| + | |- |
| + | |11q13-q14 gain / amplification |
| + | |''[[CCND1]]'', ''[[EMS1]]'', and others |
| + | |2 |
| + | |METABRIC IntClust2 |
| + | |- |
| + | |16q loss / LOH |
| + | |''[[CDH1]]'' |
| + | |2 |
| + | |METABRIC IntClust2, ER positive |
| + | |- |
| + | |17p loss / LOH |
| + | |''[[TP53]]'' |
| + | |2 |
| + | |TNBC, basal-like intrinsic subtype |
| + | |- |
| + | |17q12 amplification |
| + | |''[[ERBB2]]'' (''HER2'') |
| + | |1 |
| + | |METABRIC IntClust5, HER2-enriched |
| + | |- |
| + | |17q21 amplification |
| + | |''[[TOP2A]]'' |
| + | |2 |
| + | |METABRIC IntClust5, HER2-enriched |
| + | |- |
| + | |17q23 amplification (“17q distal amplicon”) |
| + | |''[[RPS6KB]]'', others |
| + | |2 |
| + | |METABRIC IntClust1 |
| + | |- |
| + | |19q12 |
| + | |''[[CCNE1]]'' |
| + | |2 |
| + | |METABRIC IntClust5; HER2-enriched |
| + | |- |
| + | |20q gain; 20q13 amp |
| + | |''[[AURKA]]'', ''[[GNAS]]'', ''[[ZNF217]]'' |
| + | |2 |
| + | |METABRIC IntClust1, ER Positive |
| + | |} |
| + | † See table below Table 2 for CGC Evidence levels |
| + | |
| + | Abbreviations: TNBC, triple negative breast cancer; LOH, loss of heterozygosity. |
| + | |
| + | |
| + | '''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics. |
| + | {| class="wikitable" |
| + | |'''Gene(s)''' |
| + | |'''CGC Evidence Level'''† |
| + | |'''Clinical Significance and Subgroup Association(s)''' |
| + | |'''Therapy Implication(s)''' |
| + | |- |
| + | |''[[AKT1]]'' |
| + | |2 |
| + | |Metastatic BC |
| + | |AKT inhibitors |
| + | |- |
| + | |''[[ATM]]'' |
| + | |1 |
| + | |Possible hereditary risk; TNBC |
| + | |PARP inhibitors (germline) |
| + | |- |
| + | |''[[BRCA1]], [[BRCA2]]'' |
| + | |1 |
| + | |Often hereditary risk; TNBC |
| + | |Platinum based therapy; PARP inhibitors (germline) |
| + | |- |
| + | |''[[CBFB]]'' |
| + | |2 |
| + | |ER-positive, Metastatic BC |
| + | | |
| + | |- |
| + | |''[[CCND1]], [[CCNE1]]''* |
| + | |2 |
| + | |HER2-enriched |
| + | |CDK4/6 inhibitors |
| + | |- |
| + | |''[[CDK4]], [[CDK6]]''* |
| + | |2 |
| + | |ER-positive, Metastatic BC |
| + | |CDK4/6 inhibitors |
| + | |- |
| + | |''[[CDH1]]'' |
| + | |1 |
| + | |Lobular histology; Possible hereditary risk |
| + | | |
| + | |- |
| + | |''[[CDKN2A]]'' |
| + | |2 |
| + | |Metastatic BC |
| + | | |
| + | |- |
| + | |''[[CHEK2]]'' |
| + | |1 |
| + | |Often hereditary risk |
| + | |PARP inhibitors (germline) |
| + | |- |
| + | |''[[ERBB2]]''* |
| + | |1 |
| + | |Rare activating sequence alterations; kinase domain resistance mutations; HER2-enriched |
| + | |HER2-targeted therapy |
| + | |- |
| + | |''[[ESR1]]'' |
| + | |1 |
| + | |Metastatic ER-positive |
| + | |Hormone therapy resistance |
| + | |- |
| + | |''[[FGFR1]], [[FGFR2]], [[FGFR3]], [[FGFR4]]'' |
| + | |2 |
| + | |ER-positive |
| + | |FGFR inhibitors |
| + | |- |
| + | |''[[FOXA1]]'' |
| + | |2 |
| + | |ER-positive, Luminal subtype, lobular histology |
| + | | |
| + | |- |
| + | |''[[GATA3]]'' |
| + | |2 |
| + | |ER-positive, Luminal subtype |
| + | | |
| + | |- |
| + | |''[[JAK2]]''* |
| + | |2 |
| + | |TNBC |
| + | |JAK2 inhibitors, immunotherapy |
| + | |- |
| + | |''[[MAP2K4]]'' |
| + | |2 |
| + | |Metastatic BC |
| + | | |
| + | |- |
| + | |''[[MAP3K1]]'' |
| + | |2 |
| + | |ER-positive, Metastatic BC |
| + | | |
| + | |- |
| + | |''[[MYC]]''* |
| + | |2 |
| + | | |
| + | | |
| + | |- |
| + | |''[[NBN]]'' |
| + | |1 |
| + | |Possible hereditary risk |
| + | |PARP inhibitors (germline) |
| + | |- |
| + | |''[[NF1]]'' |
| + | |1 |
| + | |Possible hereditary risk |
| + | |mTOR/PI3K/AKT inhibitors (germline) |
| + | |- |
| + | |''[[NTRK1]], [[NTRK2]], [[NTRK3]]'' |
| + | |1 |
| + | | |
| + | |NTRK inhibitors |
| + | |- |
| + | |''[[PALB2]]'' |
| + | |1 |
| + | |Often hereditary risk |
| + | |PARP inhibitors (germline) |
| + | |- |
| + | |''[[PIK3CA]]'' |
| + | |1 |
| + | |ER-Positive, Luminal subtype |
| + | |PI3K inhibitors for selected hotspot mutations; acquired hormone resistance |
| + | |- |
| + | |''[[PTEN]]'' |
| + | |2 |
| + | |Loss in lobular BC |
| + | |
| + | Possible hereditary risk |
| + | |mTOR/PI3K/AKT inhibitors; radiation contraindicated |
| + | |- |
| + | |''[[RB1]]'' |
| + | |2 |
| + | |Metastatic BC |
| + | |Acquired hormone resistance |
| + | |- |
| + | |''[[STK11]]'' |
| + | |1 |
| + | |Possible hereditary risk |
| + | | |
| + | |- |
| + | |''[[TBX3]]'' |
| + | |2 |
| + | |Lobular BC |
| + | | |
| + | |- |
| + | |''[[TOP2A]]''* |
| + | |2 |
| + | | |
| + | |Anthracycline inhibitors |
| + | |- |
| + | |''[[TP53]]'' |
| + | |1 |
| + | |TNBC, HER2-enriched, Metastatic BC |
| + | |
| + | Possible hereditary risk |
| + | |Radiation contraindicated |
| + | |} |
| + | <nowiki>*</nowiki> Indicates genes more commonly activated by amplification than by sequence variation |
| + | |
| + | Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer. |
| + | |
| + | †'''Cancer Genomics Consortium Levels of Evidence''' |
| + | {| class="wikitable" |
| + | |'''Tier''' |
| + | |'''Data Source(s)''' |
| + | |'''Interpretation''' |
| + | |- |
| + | |1 |
| + | |FDA approved therapies, professional guidelines, multiple large clinical studies |
| + | |Strong evidence supporting clinical utility of variant(s) for diagnosis, selection of therapies, or predicting disease outcome |
| + | |- |
| + | |2 |
| + | |One large study or multiple case reports |
| + | |Emerging evidence supporting clinical utility of variant(s) |
| + | |- |
| + | |3 |
| + | |Case reports or expert opinion |
| + | |Unknown clinical significance |
| + | |- |
| + | |4 |
| + | |Published evidence indicating lack of pathogenicity of variant(s) |
| + | |Benign or likely benign |
| + | |} |
| + | |
| + | |
| + | '''Table 3 - Genes with known hereditary risk associations in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics. |
| + | {| class="wikitable" |
| + | |'''Gene''' |
| + | |'''Associated Syndrome; Breast Cancer Subtype''' |
| + | |- |
| + | |''[[ATM]]'' |
| + | |Ataxia telangiectasia syndrome |
| + | |- |
| + | |''[[BARD1]]'' |
| + | |TNBC |
| + | |- |
| + | |''[[BRCA1]]'' |
| + | |[[BRCA1 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC |
| + | |- |
| + | |''[[BRCA2]]'' |
| + | |[[BRCA2 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC |
| + | |- |
| + | |''[[CDH1]]'' |
| + | |Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer |
| + | |- |
| + | |''[[CHEK2]]'' |
| + | |Inherited breast cancer |
| + | |- |
| + | |''[[NBN]]'' |
| + | |Nijmegen Breakage Syndrome |
| + | |- |
| + | |''[[NF1]]'' |
| + | |Neurofibromatosis type 1 |
| + | |- |
| + | |''[[PALB2]]'' |
| + | |Fanconi anemia |
| + | |- |
| + | |''[[PTEN]]'' |
| + | |Cowden syndrome |
| + | |- |
| + | |''[[RAD51C]]'' |
| + | |TNBC |
| + | |- |
| + | |''[[RAD51D]]'' |
| + | |TNBC |
| + | |- |
| + | |''[[STK11]]'' |
| + | |Peutz-Jeghers syndrome |
| + | |- |
| + | |''[[TP53]]'' |
| + | |Li-Fraumeni syndrome |
| + | |} |
| + | Abbreviations: TNBC, triple negative breast cancer. |
| + | ==Reference== |
| + | <references /> |